<div id="readability-page-1"><div>(TheNewswire)May 20, 2026 – TheNewswire -Toronto, Ontario, Canada - Neurothera Labs Inc. (“Neurothera” or the “Company”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (“SciSparc”), announcesthat it has adopted a semi-annual financial reporting(&#34;SAR&#34;) framework, effective immediately. This change is beingmade pursuant to the Coordinated Blanket Order 51-933 Exemptions toPermit Semi-Annual Reporting for Certain Venture Issuers(&#34;CBO 51-933&#34;).CBO 51-933 allows eligible venture issuers tovoluntarily move from a quarterly to asemi-annual financial reporting framework.Transition Details – Neurothera’s fiscal year ends onDecember 31. Under the SAR framework, the Company will be exempt fromfiling interim financial reports and related Management Discussion&amp; Analysis (“MD&amp;A”) for its first and third quartersfor so long as it continues to meet eligibility criteria under CBO51-933.By adopting the SAR, Neurothera aims to reduce theadministrative and financial burden associated with quarterlyreporting, allowing management to focus resources on advancement ofdifferent projects.<ul><li>Initial Interim Period: The Company will not file an interim report for the firstquarter (Q1) ending March 31, 2026 and for the third quarter (Q3) ending September 30, 2026.</li><li>Ongoing Reporting: Neurothera willcontinue to file audited annual consolidated financial statements (duewithin 120 days of December 31, 2026), and six-month interim financialreports (due within 60 days of June 30).</li><li>Continued Disclosure: The Company remains committed to timely disclosure and willcontinue to report all material changes and significant developmentsas required under National Instrument 51-102.</li><li>Eligibility:Neurothera confirms itmeets the pilot program's eligibility criteria, which includesbeing a venture issuer with annual revenues of less than$10 millionand maintaining a clean 12-month continuous disclosurerecord.</li><li>Continued Participation: Should the Company cease to continue participating in theSAR Pilot Program, it will announce it in a future newsrelease</li></ul>About Neurothera Labs Inc.Neurothera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.For further information, please contact:Michal Efraty IR Manager Neurothera Labs Inc.Telephone: +972-3-7617108Email: michal@efraty.comNeither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

SBIO

Neurothera Labs Inc. has adopted a semi-annual financial reporting framework effective immediately, under the CBO 51-933 exemption. This change allows the company to avoid filing interim reports for the first and third quarters, reducing administrative burdens. Neurothera will continue to file annual audited financial statements and six-month interim reports. The company confirms it meets eligibility criteria, including annual revenues under $10 million.

Neurothera Labs Announces Adoption of Semi-Annual Reporting